Funder: The Association for Frontotemporal Degeneration
Due Dates: March 30, 2026 (Letter of Intent) | June 1, 2026 (Full proposal)
Funding Amounts: Up to $2,500,000 per project over 1–3 years; payment is milestone- and enrollment-based.
Summary: Supports early-stage clinical trials for developing treatments for frontotemporal degeneration (FTD), emphasizing biomarker use and innovative trial designs.
Key Information: Open globally to academic, nonprofit, and biotech applicants; mission-related investment structure with ROI expectations.